ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2018
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04503083 (A Multidisciplinary Approach to the Identification of BIOmarkers of MIGraine), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multidisciplinary Approach to the Identification of BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.The journal of headache and pain · 2022Trial
- Trial
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).Cephalalgia : an international journal of headache · 2020Trial
- Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.European journal of neurology · 2020Trial
- Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.Headache · 2020Trial
- Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study.Frontiers in neurology · 2026Observational
- Efficacy of Desvenlafaxine in Reducing Migraine Frequency and Severity: A Retrospective Study.Journal of clinical medicine · 2024Article
- Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.Neurology international · 2024Article
- Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat.The journal of headache and pain · 2024Article
- Inhibition of Neurogenic Inflammatory Pathways Associated with the Reduction in Discogenic Back Pain.Asian spine journal · 2023Article
- Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.Inflammopharmacology · 2023Review
- Comprehensive overview of the venous disorder known as pelvic congestion syndrome.Annals of medicine · 2022Review
- Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.Health psychology research · 2022Article
- A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine.Health psychology research · 2022Review
- Rimegepant for the treatment of migraine.Health psychology research · 2022Article
- Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide's Motor-Stimulating and Prosecretory Function in the Intestine.Frontiers in physiology · 2021Review
- Review
- The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood-brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.